IntegraGen snags $2.4M to market autism Dx

Cambridge, MA-based IntegraGen pulled in $2.4 million in financing, earmarking the cash to commercialize its autism diagnostics and fund the development of its pipeline cancer tests.

The private fundraising affirms the company's status a promising producer of molecular diagnostics, IntegraGen's CEO said in a statement, especially considering the tepid venture capital climate around the industry. "This is a testimonial to investors' confidence in IntegraGen's efforts, specifically those associated with the commercialization of a genetic autism screening test this year in the U.S., as well as our progress in the field of oncology biomarkers," Bernard Courtieu said.

Back in April, IntegraGen launched Arisk Test, a gender-specific assay of genetic markers that indicate autism. The latest financing will help the company expand the test's market reach, IntegraGen said, and contribute to its R&D efforts. In the pipeline are genetic tests for colorectal and liver cancers, and the company is also working on further autism diagnostics.

The company, owned by France-based IntegraGen SA, reported revenues of $5.6 million last year.

- read the company's release
- get more from Mass High Tech

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.